Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Rev Med Interne ; 43(1): 48-53, 2022 Jan.
Article in French | MEDLINE | ID: mdl-34419323

ABSTRACT

INTRODUCTION: The Sézary syndrome (SS) is an aggressive form of cutaneous T-cell lymphoma (CTCL) requiring a rapid diagnosis due to its poor prognosis. CASE REPORT: We report the first case of an eighty-nine-year-old woman who presented with concomitant Sezary syndrome and anasarca, revealing a nephrotic syndrome caused by a minimal change nephropathy associated with immunoglobulin A (IgA) deposits. Scarce literature described rare cases associating these two entities (nephrotic syndrome and nephropathy). However, the nephrotic syndrome was delayed from disease onset, secondary to immunosuppressive treatment of SS, or due to the weaning of SS therapy. Thus, the direct link between the glomerular lesion and the cutaneous lymphoma was difficult to establish. However, the synchronous occurrence of both SS and glomerulopathy in our patient, along with Sezary cells in both urines (urinary cytology) and biopsy, and resolution of nephropathy after treatment of SS, support the likely attributability of SS in glomerulopathy. CONCLUSION: Practitioners must acknowledge the possible occurrence of glomerular involvement in SS.


Subject(s)
Glomerulonephritis, IGA , Nephrosis, Lipoid , Nephrotic Syndrome , Sezary Syndrome , Skin Neoplasms , Aged, 80 and over , Female , Glomerulonephritis, IGA/complications , Glomerulonephritis, IGA/diagnosis , Humans , Immunoglobulin A , Nephrosis, Lipoid/complications , Nephrosis, Lipoid/diagnosis , Nephrotic Syndrome/complications , Nephrotic Syndrome/diagnosis , Sezary Syndrome/complications , Sezary Syndrome/diagnosis , Skin Neoplasms/complications , Skin Neoplasms/diagnosis
2.
Ann Dermatol Venereol ; 148(3): 145-155, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33579557

ABSTRACT

Treatment of patients with melanoma has considerably improved over the past decade and more recently with adjuvant therapies for patients with American Joint Committee on Cancer (AJCC) stage III (loco-regional metastases) or IV (distant metastases) totally resected melanoma, in order to prevent recurrence. In the adjuvant setting, two options are available to patients with BRAFV600-mutant AJCC stage III totally resected melanoma: anti-PD-1 blockers (nivolumab or pembrolizumab) or BRAF plus MEK inhibitors (dabrafenib plus trametinib). In the absence of comparative studies, it is difficult to determine which of these options is best. Our aim was to review published studies focusing on the management of patients with BRAFV600-mutant melanoma in the adjuvant setting. We also reviewed the main clinical trials of BRAF plus MEK inhibitors and immunotherapy in advanced (i.e. unresectable metastatic) BRAF-mutant melanoma in an attempt to identify results potentially affecting the management of patients on adjuvants. More adverse events are observed with targeted therapy, but all resolve rapidly upon drug discontinuation, whereas with immune checkpoint blockers some adverse events may persist. New therapeutic strategies are emerging, notably neoadjuvant therapies for stage III patients and adjuvant therapies for stage II patients; the place of the adjuvant strategy amidst all these options will soon be re-evaluated. The choice of adjuvant treatment could influence the choice of subsequent treatments in neo-adjuvant or metastatic settings. This review will lead clinicians to a better understanding of the different adjuvant treatments available for patients with totally resected AJCC stage III and IV BRAFV600-mutant melanoma before considering subsequent treatment strategies.


Subject(s)
Melanoma , Skin Neoplasms , Antineoplastic Combined Chemotherapy Protocols , Humans , Melanoma/drug therapy , Melanoma/genetics , Mutation , Nivolumab/therapeutic use , Oximes/therapeutic use , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics
4.
Eur J Cancer ; 84: 44-54, 2017 10.
Article in English | MEDLINE | ID: mdl-28783540

ABSTRACT

BACKGROUND: Targeted therapy (TT) and immunotherapies (ITs) have dramatically improved survival in metastatic melanoma (MM). However, their efficacy on brain metastasis (BM) remains limited and poorly documented. PATIENTS AND METHODS: Retrospective cohort of consecutive MM patients (pts) with BMs, all systematically upfront treated by Gamma-Knife (GK) at first BM and retreated in case of new BMs, from 2010 to 2015 at the time when ipilimumab BRAF ± MEK inhibitors and anti-PD1 were introduced in practice. Survival after 1st GK (OSGK1) according to prognostic factors and treatment. RESULTS: Among 179 consecutive pts treated by GK, 109 received IT and/or TT after the 1st GK. Median OSGK1 was 10.95 months and 1- and 2-year survival rates were 49.5% and 27.4%, respectively, versus a median overall survival (OS) of 2.29 months (p < .001) in those who did not receive IT or TT. In pts who initially had a single BM, median OS and 1- and 2-year survival rates were 14.46 months, 66.7% and 43.4%, respectively; in pts with 2-3 BMs: 8.85 months, 46.4% and 31%, respectively; in pts with >3 BMs: 7.25 months, 37.2% and 11.9%, respectively. Multivariate analysis for OSGK1 confirmed that IT and TT were significantly and highly protective. Best OSGK1 was observed in BRAF-wild-type pts receiving anti-PD1 or in BRAF-mutated pts receiving BRAF-inhibitors and anti-PD1 (12.26 and 14.82 months, respectively). CONCLUSION: In real-life MM pts with BMs, a strategy aiming at controlling BM with GK together with TT and/or TT seems to achieve unprecedented survival rates.


Subject(s)
Antibodies/therapeutic use , Antineoplastic Agents/therapeutic use , Brain Neoplasms/therapy , Immunotherapy/methods , Melanoma/therapy , Molecular Targeted Therapy/methods , Protein Kinase Inhibitors/therapeutic use , Radiosurgery/methods , Skin Neoplasms/therapy , Antibodies/adverse effects , Antineoplastic Agents/adverse effects , Brain Neoplasms/enzymology , Brain Neoplasms/mortality , Brain Neoplasms/secondary , Chemotherapy, Adjuvant , Female , Humans , Immunotherapy/adverse effects , Kaplan-Meier Estimate , MAP Kinase Kinase Kinases/antagonists & inhibitors , MAP Kinase Kinase Kinases/metabolism , Male , Melanoma/enzymology , Melanoma/mortality , Melanoma/secondary , Middle Aged , Molecular Targeted Therapy/adverse effects , Multivariate Analysis , Mutation , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/immunology , Proportional Hazards Models , Protein Kinase Inhibitors/adverse effects , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/metabolism , Radiosurgery/adverse effects , Retrospective Studies , Risk Factors , Skin Neoplasms/enzymology , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Time Factors , Treatment Outcome
5.
Ann Dermatol Venereol ; 141(5): 364-8, 2014 May.
Article in French | MEDLINE | ID: mdl-24835649

ABSTRACT

BACKGROUND: Primary cutaneous plasmacytoma is a rare form of cutaneous B-cell lymphoma. PATIENTS AND METHODS: A 51 year-old male with an unremarkable history gradually presented erythematous papulonodular lesions that had appeared gradually over the whole body throughout a two-year period and showing histologic and immunohistochemical features of cutaneous plasmacytoma. Staging investigations confirmed the primary character of the disease, and because of this and the absence of functional impairment, we opted for therapeutic abstention. No progression was noted after 4 years of regular monitoring. DISCUSSION: Primary cutaneous plasmacytoma (PCP) is characterized by clonal proliferation of plasma cells in skin. Multiple PCPs are extremely rare and to date have been treated in most cases by chemotherapy, either with or without radiotherapy. The prognosis is poor, with 2-year survival of only 25%. The present case is original, being the only one to our knowledge in which therapeutic abstention was followed by a lack of progression after 4 years of regular follow-up. Consequently, certain indolent forms of PCP do not warrant automatic institution of chemotherapy.


Subject(s)
Neoplasms, Multiple Primary/pathology , Plasmacytoma/pathology , Skin Neoplasms/pathology , Humans , Male , Middle Aged , Multiple Myeloma/pathology , Neoplasms, Multiple Primary/therapy , Plasmacytoma/therapy , Skin Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...